Misplaced Pages

Amonafide: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 01:28, 6 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'DrugBank_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|erro← Previous edit Revision as of 19:24, 7 August 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|errorsNext edit →
Line 1: Line 1:
{{drugbox {{drugbox
| UNII_Ref = {{fdacite|correct|FDA}}
| Verifiedfields = changed
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 1Q8D39N37L | UNII = 1Q8D39N37L
| verifiedrevid = 403349247 | verifiedrevid = 443275125
| IUPAC_name = 5-amino-2--1''H''-benzoisoquinoline-1,3(2''H'')-dione | IUPAC_name = 5-amino-2--1''H''-benzoisoquinoline-1,3(2''H'')-dione
| image = Amonafide.svg | image = Amonafide.svg

Revision as of 19:24, 7 August 2011

Pharmaceutical compound
Amonafide
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 5-amino-2--1H-benzoisoquinoline-1,3(2H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H17N3O3
Molar mass283.325 g/mol g·mol
3D model (JSmol)
SMILES
  • O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI
  • InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3
  • Key:UPALIKSFLSVKIS-UHFFFAOYSA-N
  (verify)

Amonafide (originally AS1413) (INN, trade name Quinamed) is a drug that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and DNA intercalators.

It is being developed as an anti-cancer therapy by Antisoma.

As of 2008, it is in Phase III clinical trials. eg In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).

References

  1. http://www.genengnews.com/news/bnitem.aspx?name=78979622
  2. http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"

External links

Public Domain This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Amonafide: Difference between revisions Add topic